The Evolving Unmet Need for High Dose Inhaled Therapies in Orphan Lung Diseases
Hofmann T, Ufer S, Canisius S.
Respiratory Drug Delivery 2024. Volume 1, 2024: 123-129.
Abstract:
Inhaled therapies for orphan lung disease have evolved to prolong the lives of an increasing number of patients but remain an unmet medical need. Many learnings related to dosing, formulation, preclinical and clinical endpoints have provided a basis for ongoing and future developments to help more individuals with severe and rare diseases.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
